The efficacy and safety of low-molecular-weight heparins for venous thromboembolism prophylaxis in abdominal or pelvic cancer surgery: A systematic review and network meta-analysis of randomized controlled trials

被引:0
|
作者
Liu, Kun [1 ]
Hu, Can [1 ]
Zhou, Ling-yun [1 ]
Tang, Zhi-yao [1 ]
Wu, Yi-feng [1 ]
Huang, Yu-jie [1 ]
Zuo, Xiao-cong [1 ,2 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Hunan, Peoples R China
关键词
Low-molecular-weight heparins; Cancer; Abdominal or pelvic cancer surgery; Venous thromboembolism; Hemorrhage; Network meta-analysis; PNEUMATIC COMPRESSION; PREVENTION; ENOXAPARIN; SURVIVAL; DEFINITION; GUIDELINES; MANAGEMENT; BREAST;
D O I
10.1016/j.thromres.2025.109294
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Low-molecular-weight heparins (LMWHs) have been widely used for thromboprophylaxis in postoperative patients with abdominal or pelvic cancer. However, evidence regarding the optimal type of LMWHs remains limited. Objective: This study aims to evaluate the efficacy and safety of different types of LMWHs in patients undergoing abdominal or pelvic cancer surgery through a network meta-analysis of randomized controlled trials (RCTs). Methods: The network meta-analysis was guided by the PRISMA guidelines. The primary outcomes included venous thromboembolism (VTE), major bleeding, and all-cause death. Results were summarized with relative ratios (RR) and 95 % confidence intervals (CIs). The surface under the cumulative ranking curve (SUCRA) was calculated to assess the performance of various LMWHs. Results: A total of 19 RCTs involving 6318 patients were identified. Compared to non-LMWH, LMWHs significantly reduced the risk of VTE [RR 0.57, (95 % CI 0.41-0.81)], DVT [RR 0.56, (95 % CI 0.39-0.81)], and PE [RR 0.26, (95 % CI 0.10-0.66)], without increasing the risk of all-cause death [RR 0.67, (95 % CI 0.39-1.14)], major bleeding [RR 1.51, (95 % CI 0.82-2.77)], minor bleeding [RR 1.23, (95 % CI 0.84-1.80)], all bleeding [RR 1.35, (95 % CI 0.98-1.84)], or thrombocytopenia [RR 0.41, (95 % CI 0.13-1.31)]. Notably, no significant differences in efficacy and safety were observed among different types of LMWHs, with parnaparin (SUCRA 86.3), dalteparin (SUCRA 74.5), and certoparin (SUCRA 88.5) ranking highest in the prevention of VTE, major bleeding, and allcause death, respectively. Conclusion: LMWHs are efficacious options for thromboprophylaxis in patients undergoing abdominal or pelvic cancer surgery, without increasing the risk of major bleeding or all-cause death. However, no significant differences were observed in efficacy and safety among different types of LMWHs used in this context.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The efficacy of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after knee and hip arthroplasty: A systematic review and meta-analysis of randomized controlled trials
    Salman, Loay A.
    Altahtamouni, Seif B.
    Khatkar, Harman
    Al-Ani, Abdallah
    Hameed, Shamsi
    Alvand, Abtin
    KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2025, 33 (05) : 1605 - 1616
  • [2] The treatment of venous thromboembolism with low-molecular-weight heparins A meta-analysis
    Bochenek, Tomasz
    Nizankowski, Rafal
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (04) : 699 - 716
  • [3] Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness
    Dranitsaris, George
    Shane, Lesley G.
    Woodruff, Seth
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 68 - 75
  • [4] Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
    Fu, Weijie
    Zhao, Maolin
    Ding, Sheng
    Xin, Mei
    Yang, Ke
    Jiang, Li
    Wu, Fan
    Wu, Xiaochen
    Wang, Jian
    Chen, Jie
    Gao, Feng
    He, Siyi
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [5] Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients
    Dooley, Christopher
    Kaur, Rajbir
    Sobieraj, Diana M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (03) : 367 - 380
  • [6] Safety and Efficacy of Bridging with Low Molecular Weight Heparins: A Systematic Review and Partial Meta-Analysis
    Eijgenraam, Pieter
    ten Cate, Hugo
    ten Cate-Hoek, Arina
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (22) : 4014 - 4023
  • [7] Safety and efficacy of ximelagatran: Meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism
    Iorio, A
    Guercini, F
    Ferrante, F
    Nenci, GG
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (30) : 3893 - 3918
  • [8] The role of anticoagulation in venous thromboembolism primary prophylaxis in patients with malignancy: A systematic review and meta-analysis of randomized controlled trials
    Barbarawi, Mahmoud
    Zayed, Yazan
    Kheiri, Babikir
    Gakhal, Inderdeep
    Barbarawi, Owais
    Bala, Areeg
    Alabdouh, Ahmad
    Abdalla, Ahmed
    Rizk, Fatima
    Bachuwa, Ghassan
    Katato, Khalil
    THROMBOSIS RESEARCH, 2019, 181 : 36 - 45
  • [9] The efficacy and safety of low-molecular-weight heparin use for cancer treatment: A meta-analysis
    Che, D. H.
    Cao, J. Y.
    Shang, L. H.
    Man, Y. C.
    Yu, Y.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (05) : 433 - 439
  • [10] Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis
    Dong, Ying
    Wang, Yi
    Ma, Rui-Lian
    Liu, Ming
    Gao, Jun-zhen
    Su, Wu-yun
    Yan, Li
    Sun, Jian-jun
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (03) : 400 - 412